Product Description
Mechanisms of Action: Protein Synthesis Inhibitor
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Topical,Ophthalmic
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Okogen
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Conjunctivitis, Viral
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| RUBY | P2 |
Recruiting |
Conjunctivitis, Viral |
2020-06-30 |